» Authors » Paola Luciani

Paola Luciani

Explore the profile of Paola Luciani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 92
Citations 1149
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Coones R, Coones R, Nikolic I, Eugster R, Mehn D, Tong V, et al.
Int J Pharm . 2025 Mar; 674:125452. PMID: 40064381
Iron sucrose is used in the parenteral treatment of iron deficiency anaemia. A number of iron sucrose similars have been developed alongside the original product. These products consist of colloidal...
2.
Valentino G, Widak A, Scopacasa B, Tirinato L, Parrotta E, Perozziello G, et al.
J Mater Chem B . 2025 Mar; PMID: 40029112
Liver fibrosis resulting from chronic liver injury is characterized by increased extracellular matrix deposition and inflammation, which leads to excessive scar tissue formation. Targeting activated hepatic stellate cells (HSCs), which...
3.
Teworte S, Behrens M, Widhe M, Gurzeler L, Hedhammar M, Luciani P
Small . 2025 Feb; :e2409126. PMID: 39967482
This study advances sustainable pharmaceutical research for endometriosis by developing in vitro 3D cell culture models of endometriotic pathophysiology that allow antifibrotic drug candidates to be tested. Fibrosis is a...
4.
Eugster R, Orsi M, Buttitta G, Serafini N, Tiboni M, Casettari L, et al.
J Control Release . 2024 Nov; 376:1025-1038. PMID: 39489466
Drug delivery systems efficiently and safely administer therapeutic agents to specific body sites. Liposomes, spherical vesicles made of phospholipid bilayers, have become a powerful tool in this field, especially with...
5.
Xin L, Madarasz A, Ivan D, Weber F, Aleandri S, Luciani P, et al.
J Neuroinflammation . 2024 Oct; 21(1):272. PMID: 39444001
Accumulation of immune cells and proteins in the subarachnoid space (SAS) is found during multiple sclerosis and in the animal model experimental autoimmune encephalomyelitis (EAE). Whether the flow of cerebrospinal...
6.
Gazzi R, Gelli R, Eugster R, Buhr C, Schurch S, Mezzenga R, et al.
J Colloid Interface Sci . 2024 Sep; 678(Pt C):595-607. PMID: 39305627
Lipidic mesophase drug carriers have demonstrated the capacity to host and effectively deliver a wide range of active pharmaceutical ingredients, yet they have not been as extensively commercialized as other...
7.
Gazzi R, Gelli R, Aleandri S, Carone M, Luciani P
Wiley Interdiscip Rev Nanomed Nanobiotechnol . 2024 Aug; 16(4):e1986. PMID: 39140489
Due to its chronic nature and complex pathophysiology, inflammatory bowel disease (IBD) poses significant challenges for treatment. The long-term therapies for patients, often diagnosed between the ages of 20 and...
8.
Arenas Hoyos I, Helmer A, Yerly A, Lese I, Hirsiger S, Zhang L, et al.
Front Immunol . 2024 Jun; 15:1387945. PMID: 38887281
Introduction: The standard treatment for preventing rejection in vascularized composite allotransplantation (VCA) currently relies on systemic immunosuppression, which exposes the host to well-known side effects. Locally administered immunosuppression strategies have...
9.
Allegritti E, Giansanti L, Bordon G, Maggi M, Luciani P, Aleandri S
J Colloid Interface Sci . 2024 Mar; 664:1031-1041. PMID: 38521004
In this study, we explored the use of lipid mesophases (LMPs) as a biocompatible and biodegradable material for sustained drug delivery. Our hypothesis centered on leveraging the high surface-to-volume ratio...
10.
Dzhumashev D, Anton-Joseph S, Morel V, Timpanaro A, Bordon G, Piccand C, et al.
Eur J Pharm Biopharm . 2023 Nov; 194:49-61. PMID: 38029941
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. More effective and less toxic therapies are urgently needed for high-risk patients. Peptide-guided targeted drug delivery can increase the therapeutic...